Boehringer Ingelheim, a pharmaceutical company, and Microsoft have announced a partnership to explore how artificial intelligence (AI) can improve the process of developing new medicines. The goal is to make clinical trials more efficient, which could help get new treatments to patients faster. One of the main focuses of this collaboration will be on creating ‘digital patient twins’—virtual models that mimic real patients. These digital twins could help reduce the number of people needed in control groups during trials, improve how clinical evidence is gathered, and even create simulated control groups to make trials more accurate. The partnership will start by focusing on lung health. Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, explained that the company wants clinical research to better address the needs of patients. By using AI and digital twins, the company hopes to make trials more patient-focused, informative, and efficient. As part of this effort, Boehringer will also modernize its data centers and security systems to support future AI innovations. If this collaboration is successful, it could speed up the development of new drugs and give patients quicker access to life-saving treatments. This partnership aligns with recent regulatory efforts to support AI in medicine. For example, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) launched an AI initiative in June to enhance medicine safety. The UK Health Innovation Minister, Preet Gill, stated that this initiative provides a safe space for companies and researchers to test AI tools under regulatory supervision, helping to build the evidence needed to bring safer and more effective treatments to patients faster.